A Double Blind, Placebo-controlled Study to Assess the Anti-viral Effect, Safety and Tolerability of Inhaled PC786 for the Treatment of Acute Respiratory Syncytial Virus (RSV) Infection in Adult Hematopoietic Stem Cell Transplant Recipients
Phase of Trial: Phase II
Latest Information Update: 06 Dec 2019
Price : $35 *
At a glance
- Drugs PC-786 (Primary) ; Immunoglobulins; Ribavirin
- Indications Respiratory syncytial virus infections
- Focus Adverse reactions; Therapeutic Use
- Acronyms TreatRSV1
- Sponsors Pulmocide
- 10 Jun 2019 Status changed from active, no longer recruiting to discontinued.
- 03 Apr 2019 Status changed from recruiting to active, no longer recruiting.
- 09 Nov 2018 Status changed from not yet recruiting to recruiting.